UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for ...

(RTTNews) - UroGen Pharma Ltd. (URGN), Tuesday announced data from a long-term follow-up study with Jelmyto for pyelocalyceal solution, an FDA approved for the treatment of low-grade, upper tract ...

On Tuesday, H.C. Wainwright maintained its Buy rating and $60.00 stock price target for UroGen Pharma (NASDAQ:URGN), following the company's announcement last week of a new Chief ...

UroGen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 ...

What you need to know Microsoft is revitalizing the MSN brand with a fresh new logo as it replaces "Microsoft Start" branding in Edge. In a statement to Windows Central, Microsoft has confirmed ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.82. Operator: Good ...

免费获得UroGen Pharma(URGN)期权数据。查看选定到期日的UroGen Pharma个股期权的认购、认沽执行价格、最新价、涨跌幅、成交量及更多股票期权相关信息。点击“分析”可查看UroGen Pharma Ltd股票期权的未平仓合约分析表格。

Urogen Pharma ( (URGN)) has released its Q3 earnings. Here is a breakdown of the information Urogen Pharma presented to its investors. UroGen Pharma Ltd. is a biotechnology company focused on ...

Good morning, ladies and gentlemen. Thank you for standing by and welcome to the UroGen Pharma Third Quarter 2024 Earnings Call. Please be advised that today's conference is being recorded.

Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago. These figures ...